36
Participants
Start Date
May 11, 2022
Primary Completion Date
January 29, 2025
Study Completion Date
January 29, 2025
OKI-179 + binimetinib
"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
Memorial Sloan-Kettering Cancer Center, New York
University of Virginia Health System, Charlottesville
CTCA Atlanta, part of City of Hope, Newnan
Emory University Winship Cancer Institute, Atlanta
University of Florida Health Cancer Center, Gainesville
Sarah Cannon Research Institute, Nashville
Henry Ford Health System, Detroit
CTCA Chicago, part of City of Hope, Zion
University of Texas MD Anderson Cancer Center, Houston
CTCA Phoenix, part of City of Hope, Phoenix
University of California, San Francisco, San Francisco
Massachusetts General Hospital, Boston
OnKure, Inc.
INDUSTRY